Given this information, it is important to determine whether the presentation of these two hallmark pathologies also displays heterogeneity in APOE4+ vs. APOE4− AD patients, and how this presentation may relate to the differences in brain atrophy and cognitive deficits that are observed in these patients. The gene discussed is APOE; the disease is Cognitive impairment.